11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol | 56354-06-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol
• 英文别名: 11-Nor-9-carboxy-thc；1-hydroxy-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid
• CAS: 56354-06-4
• 化学式: C₂₁H₂₈O₄
• 分子量: 344.451
• InChiKey: YOVRGSHRZRJTLZ-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  密封，在-20°C下保存

反应信息

• 作为反应物：
  描述：

  DL-高半胱氨酸硫内酯盐酸盐 、 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol 在 吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 反应 6.0h， 生成 9-N-(2-butyrothiolactone)amido-11-Δ9-THC
  参考文献：
  名称：

  [EN] TETRAHYDROCANNABINOID- PROTEIN CONJUGATES FOR THE PRODUCTION OF ANTIBODIES FOR THE DETECTION OF T?TRAHYDROCANNABINOID COMPONENTS IN SALIVA
  [FR] ANTIGENES TETRAHYDROCANNABINOIDES ET LEUR PROCEDE D'UTILISATION

  摘要：

  公开号：

  WO2006029089A3

文献信息

• Identification in human urine of Δ9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite
  作者：P L Williams、A C Moffat

  DOI：10.1111/j.2042-7158.1980.tb12966.x

  日期：2011.4.12

  A Δ9 -THC metabolite has been identified in human urine as an ester linked glucuronide of Δ9 -THC-11-oic acid. Its identity was established by a comparison of mass spectra from the metabolite extracted from human urine and synthetically prepared material. Δ9 -THC-11-oic acid glucuronide was found to be responsible for the major part of RIA crossreactivity in urine with the Guildhay cannabinoid antiserum used in this study.

  在人类尿液中，已经鉴定出一种Δ9-THC代谢物，它是Δ9-THC-11-油酸的酯化葡萄糖醛酸。通过比较从人类尿液中提取的代谢物和合成制备材料的质谱图，确定了其身份。本研究中使用的Guildhay大麻素抗血清与尿液中的Δ9-THC-11-油酸葡萄糖醛酸反应交叉性的主要部分。

• Compounds for fluoroscense polarization immunoassays and immunoassays utilising them
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0597333A2

  公开（公告）日：1994-05-18

  Compounds of the formula wherein F is a fluorescing compound; Y is -NH- or a single covalent bond; Z is a straight or branched alkylene chain of 2 to 10 carbon atoms which is substituted by at least one hydrophilic group; Q is oxygen or sulfur; and X is a ligand-analog, the ligand-analog capable of being recognized by an antibody specific to the corresponding ligand. These compounds have improved properties in fluorescence polarization immunoassays by possessing either a better intensity and/or a larger span.

  式中的化合物 其中 F 是荧光化合物；Y 是-NH-或单个共价键；Z 是 2 至 10 个碳原子的直链或支链亚烷基链，至少被一个亲水基团取代；Q 是氧或硫；X 是配体类似物，配体类似物能够被相应配体的特异性抗体识别。这些化合物具有更好的强度和/或更大的跨度，从而改善了荧光偏振免疫分析的性能。
• Extraction, derivatization, and quantification of analytes
  申请人：SPEware Corporation

  公开号：US10267775B2

  公开（公告）日：2019-04-23

  The present specification discloses methods for determining the presence one or more analytes in a test sample, materials useful to perform the disclosed methods, and kits comprising reagents useful to practice the disclosed methods.

  本说明书公开了用于确定测试样本中是否存在一种或多种分析物的方法、用于执行所公开方法的材料，以及包含用于实施所公开方法的试剂的试剂盒。
• Compound and method for treatment of diseases and disorders
  申请人：Kariman Alexander

  公开号：US10307392B2

  公开（公告）日：2019-06-04

  The disclosed invention generally relates to treatment and/or prevention of symptoms associated with cannabinoid responsive diseases and disorders in subjects in need thereof, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids. The disclosed invention further relates to pharmaceutical compounds for treating and/or preventing symptoms associated with said diseases and disorders.

  所公开的发明一般涉及治疗和/或预防有需要的受试者中与大麻素反应性疾病和紊乱相关的症状，以及施用治疗有效量的含大麻素的药用化合物的方法。本发明还涉及用于治疗和/或预防上述疾病和紊乱相关症状的药物化合物。
• Method for target substance detection and measurement
  申请人：Hound Labs, Inc.

  公开号：US10408850B1

  公开（公告）日：2019-09-10

  Various embodiments for a hand-held device to determine a level of one or more cannabinoid compounds in exhaled human breath are provided; some embodiments may also determine a level of alcohol in the exhaled breath. The device may perform any of the following steps: capture, concentrate, separate, identify, and quantify the level of cannabinoids in the exhaled human breath. The device may use solvent extraction and liquid chromatography to concentrate and separate cannabinoids from breath contaminants, followed by selective chemical modification of the cannabinoids with a fluorescent indicator for quantification. The measurement methodology may also include real time calibration of the device and detection protocol using known cannabinoid standards, which are simultaneously analyzed along with an unknown, to quantify the level of cannabinoids captured from the breath sample. The capture and separation components, along with cannabinoid analysis standards, may be configured as part of a single-use, field-replaceable testing cartridge.

  提供了用于确定呼出的人体口气中一种或多种大麻化合物含量的手持设备的各种实施例；某些实施例还可确定呼出的口气中的酒精含量。该设备可执行以下任何步骤：捕获、浓缩、分离、识别和量化呼出的人体口气中的大麻素含量。该装置可使用溶剂萃取和液相色谱法浓缩大麻素并将其从呼气污染物中分离出来，然后用荧光指示剂对大麻素进行选择性化学修饰以进行量化。测量方法还可包括使用已知大麻素标准品对设备和检测协议进行实时校准，同时分析未知标准品，以量化从呼气样本中捕获的大麻素含量。捕获和分离组件以及大麻素分析标准可以配置为一次性使用、可现场更换的检测盒的一部分。